Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

i. Initial Dose

For patients with a hemoglobin level less than 6 mg/dl, an initial dose of 32.5 g (one unit)
of HBOC 201 is recommended, to be followed by infusion of additional units as necessary to
achieve and maintain a total hemoglobin concentration above 6 g/dl, provided that the
patient's circulatory volume is properly controlled and will not impose an inappropriate
risk.

ii. Subsequent Doses

The need for additional dose administration should be assessed after each infusion as
clinically indicated.

Dosing will be stopped if any one of the following occurs:

- resolution of critical ischemia

- death

- recovery of native Hemoglobin levels to > 6 g/dL,

- evidence of reticulocytosis

Inclusion Criteria:

1. Patients > = 18 years of age

2. Patients with hemoglobin < = 8g/dL with with active bleeding, physiologic evidence of
critical ischemia, for example: elevated troponins, altered mental status, acute renal
failure, lactic acidosis or central nervous system supply dependency

3. Patients or their Legally Authorized Representatives who are able and willing to
provide informed consent

Exclusion Criteria:

1. Patients with known hypersensitivity or allergy to beef products

2. Patients with pre-existing uncontrolled hypertension, heart failure, renal failure,
circulatory hypervolemia or systemic mastocytosis (on a case by case and quality of
life determination)

3. Patients > 80 years of age (on a case by case and quality of life determination)

4. Patients who are eligible for blood transfusions